Medically reviewed by Sohaib Imtiaz, MD Semaglutide is an injectable medication available as Ozempic and Rybelsus to treat ...

Rybelsus (semaglutide) is an oral medication used in combination with exercise and a healthy diet to help treat type 2 diabetes. It’s best taken on an empty stomach but isn’t known to interact ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney disease, ...

India's anti-obesity drug market shows significant growth. It has increased fourfold in five years. Lifestyle diseases and ...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025.

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven ...